No Evidence of Overweight in Long-Term Survivors of Childhood Cancer After Glucocorticoid Treatment.

TitreNo Evidence of Overweight in Long-Term Survivors of Childhood Cancer After Glucocorticoid Treatment.
Publication TypeJournal Article
Year of Publication2018
AuthorsBelle, F, Kasteler, R, Schindera, C, Bochud, M, Ammann, RA, von der Weid, NX, Kuehni, CE
Corporate AuthorsSwiss Pediatric Oncology Group (SPOG)
JournalCancer
Volume124
Issue17
Pagination3576-3585
Date Published09/2018
DOI10.1002/cncr.31599
ISSN1097-0142
Mots-clésChildhood cancer survivors, cranial radiotherapy (CRT), Europe, late effects, Obesity, Steroids, Swiss Childhood Cancer Registry
Abstract

BACKGROUND: Glucocorticoids can lead to weight gain during cancer treatment, but to the authors' knowledge, little is known regarding their long-term effects in childhood cancer survivors (CCS).

METHODS: As part of the Swiss Childhood Cancer Survivor Study, the authors sent a questionnaire to CCS aged <21 years at diagnosis who were residing in Switzerland, had survived ≥5 years, and were aged 15 to 45 years at the time of the survey. Cumulative doses of glucocorticoids were assessed from medical records and study protocols and body mass index was calculated from self-reported height and weight at the time of the survey. The authors compared the prevalence of overweight between CCS, their siblings, and the general population (Swiss Health Survey [SHS]) and investigated the association between overweight and treatment-related risk factors using multivariable logistic regression.

RESULTS: The study included 1936 CCS, 546 siblings, and 9591 SHS participants. The median age of the CCS at the time of the survey was 24 years (interquartile range, 20-31 years) and the median time since diagnosis was 17 years (interquartile range, 12-22 years). At the time of the survey, approximately 26% of CCS were overweight, a percentage that was comparable to that among siblings (24%) and the SHS participants (25%). The prevalence of overweight was 24% in CCS treated with glucocorticoids only (686 CCS), 37% in those treated with cranial radiotherapy (CRT) (127 CCS), and 49% in those who received treatment with both glucocorticoids and CRT (101 CCS) (P < .001). The authors found no evidence of a dose-response relationship between cumulative glucocorticoid doses and overweight and no evidence that CRT modified the effect of the cumulative glucocorticoid dose on overweight.

CONCLUSIONS: The results of the current study suggest that glucocorticoids used for the treatment of childhood cancer are not associated with long-term risk of overweight.

Alternate URL

http://www.ncbi.nlm.nih.gov/pubmed/30119140?dopt=Abstract

First publication date (online)

08/2018

WOS ID (UT)

000447376600014

Alternate JournalCancer
Citation Key / SERVAL ID9065
Peer reviewRefereed
PubMed ID30119140
                         

IUMSP | www.iumsp.ch
Institut universitaire de médecine sociale et préventive
Route de la Corniche 10, 1010 Lausanne - Switzerland
+41 21 314 72 72 | iumsp@chuv.ch

Go to top